90% CI of ratio of SDs for NTI drugs [RSABE / ABEL]

posted by Satish – India, 2015-07-15 10:35 (4001 d 09:18 ago) – Posting: # 15083
Views: 6,380

Dear all,

As we know for NTI drugs guidelines Warfarin has suggested that use both (1) scaled and unscaled ABE, in addition to that (2) calculation of 90% CI of ratio of within subject standard deviation of test to reference product.

here my problem is (2). i don't know how to calculate (2). but i tried it with 'COVPRMS' of 'PROC MIXED' from normal ln transformed data (not from ilat, dlat). i calculated within subject standard deviation for test and reference using 'estimates' in 'COVPRMS'. now i just want to know am i doing it in the correct way or not?

Thanks and Regards,
Satish.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
164 visitors (0 registered, 164 guests [including 13 identified bots]).
Forum time: 19:54 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5